Main Article Content
Objective: To determine the frequency of pulmonary hypertension among patients with idiopathic pulmonary fibrosis using echocardiography, presenting to the Pulmonology Department of a tertiary care hospital.
Methodology: This cross-sectional study was conducted on a sample size of 130 patients (aged 50-80 years) with idiopathic pulmonary fibrosis presented to the Department of Pulmonology, Jinnah Hospital Lahore from September 2018 to March 2019. Mean pulmonary artery pressure (mPAP) 25 mmHg at rest was regarded to be pulmonary hypertension, whilst mPAP of 25–40 mmHg at rest was deemed to be moderate pulmonary hypertension, and mPAP >40 mmHg at rest was considered to be a serious disease. Data was analyzed using SPSS v.17.0. Numerical variables were summarized as mean and standard deviation. Chi-square test was used as a test of significance and a p-value < 0.05 was considered as significant.
Results: Mean age was 64.5+8.7 years with 67 (51.5%) male and 63 (48.5%) female. The mean duration of the disease since diagnosis of Idiopathic Pulmonary Fibrosis was 13.6+6.4 months. After doing echocardiography, pulmonary hypertension was found in 19 (14.6%) patients with moderate pulmonary hypertension in 14 (10.7%) while 5 (3.8%) had severe disease. Mean mPAP was 19.2+9.2 mmHg (mPAP 10-50 mmHg).
Conclusion: Pulmonary Hypertension is not an uncommon finding in patients with Idiopathic Interstitial Fibrosis. Prevalence of pulmonary hypertension had no association with the finding of this study. Moreover, no association of age, sex, or duration of disease with the prevalence of pulmonary hypertension was seen.
Work published in JPMI is licensed under a
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Raghu G, Collard HR, Egan JJ, Marti¬nez FJ, Behr J, Brown KK, et al. ATS/ ERS/JRS/ALAT Committee on Idiopath¬ic Pulmonary Fibrosis. An official ATS/ ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and manage¬ment. Am J Respir Crit Care Med. 2011 15;183(6):788-824. DOI: 10.1164/rc¬cm.2009-040GL.
Rivera-Lebron B. Pulmonary hyperten¬sion in idiopathic pulmonary fibrosis. Adv Pulm Hypertens. 2013;12:3:127-134. DOI:10.21693/1933-088x-12.3.127
Nathan SD, Shlobin OA, Weir N, Ah¬mad S, Kaldjob JM, Battle E, et al. Long-term course and prognosis of id¬iopathic pulmonary fibrosis in the new millennium. Chest. 2011;140(1):221-9. DOI:10.1378/chest.10-2572.
Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest. 2007;132(3):998-1006. DOI:10.1378/ chest.06-3087.
Andersen CU, Mellemkjær S, Hilberg O, Nielsen-Kudsk JE, Simonsen U, Bend¬strup E. Pulmonary hypertension in in¬terstitial lung disease: prevalence, prog¬nosis, and 6 min walk test. Respir Med. 2012;106(6):875-82. DOI:10.1016/j. rmed.2012.02.015.
Rivera-Lebron BN, Forfia PR, Kreider M, Lee JC, Holmes JH, Kawut SM. Echocar¬diographic and hemodynamic predic¬tors of mortality in idiopathic pulmonary fibrosis. Chest. 2013;144(2):564-570. DOI:10.1378/chest.12-2298.
Castria D, Refini RM, Bargagli E, Mezzasalma F, Pierli C, Rottoli P. Pul¬monary hypertension in idiopathic pulmonary fibrosis: prevalence and clinical progress. Int J Immuno¬ pathol Pharmacol. 2012;25(3):681-9. DOI:10.1177/039463201202500314.
Papakosta D, Pitsiou G, Daniil Z, Dimadi M, Stagaki E, Rapti A, Antoniou K, et al. Prevalence of pulmonary hypertension in patients with idiopathic pulmonary fibrosis: correlation with physiological parameters. Lung. 2011;189(5):391-9. DOI:10.1007/s00408-011-9304-5.
Humbert M, Lau EM, Montani D, Jaïs X, Sitbon O, Simonneau G. Advances in therapeutic interventions for patients with pulmonary arterial hypertension. Circulation. 2014;130(24):2189- 208.DOI:10.1161/CIRCULATIONA¬HA.114.006974.
Nickel N, Golpon H, Greer M, Knud¬sen L, Olsson K, Westerkamp V, et al. The prognostic impact of follow-up assessments in patients with idiopath¬ic pulmonary arterial hypertension. Eur Respir J. 2012;39(3):589-96. DOI:10.1183/09031936.00092311.
Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A me¬ta-analysis of randomized controlled trials in pulmonary arterial hyperten¬sion. Eur Heart J. 2009;30(4):394-403. DOI:10.1093/eurheartj/ehp022.
Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Hervé P, et al. Long-term intra¬venous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardi¬ol. 2002;40(4):780-8. DOI:10.1016/ s0735-1097(02)02012-0.
Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, et al. The REVEAL Registry risk score cal¬culator in patients newly diagnosed with pulmonary arterial hypertension. Chest. 2012;141:354-62.DOI:10.1378/ chest.11-0676.
Benza RL, Miller DP, Barst RJ, Bad¬esch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary ar¬terial hypertension from the REVEAL Registry. Chest. 2012;142:448-56. DOI:10.1378/chest.11-1460.
Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301-15. DOI:10.1164/ajrccm.157.4.9707039.
Shapiro S, Traiger GL, Turner M, Mc¬Goon MD, Wason P, Barst RJ. Sex differ¬ences in the diagnosis, treatment and outcome of patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term pulmonary arterial hypertension disease management. Chest. 2012;141:363. DOI:10.1378/chest.10-3114.
Hoeper MM, Galié N, Murali S, Olschews¬ki H, Rubenfire M, Robbins IM, et al. Outcome after cardiopulmonary resus¬citation in patients with pulmonary arte¬rial hypertension. Am J Respir Crit Care Med. 2002;165:341-4. DOI:10.1164/ ajrccm.165.3.200109-0130c.